Structural Biology Program
The Christopher Lima Lab
We are a basic research laboratory that studies the structural, biochemical, and functional basis for macromolecules involved in post-translational protein modification by ubiquitin and ubiquitin-like proteins such as SUMO, and pathways that contribute to co- and post-transcriptional RNA maturation, processing and decay. We pursue biochemical approaches to reconstitute key intermediates or complexes in these pathways and combine them with single particle cryo-EM and x-ray crystallography in conjunction with genetics and biochemistry to elucidate structure/activity relationships.
Das, M., Zattas, D., Zinder, J.C., Wasmuth, E.V., Henri, J., Lima, C.D. Substrate discrimination and quality control require each catalytic activity of TRAMP and the nuclear RNA exosome. Proc Natl Acad Sci U S A. 118:e2024846118. (2021) [PMID: 33782132]
Hann, Z.S., Ji, C., Olsen, S.K., Lu, X., Lux, M.C., Tan, D.S., Lima, C.D.Structural basis for adenylation and thioester bond formation in the ubiquitin E1. Proc Natl Acad Sci U S A. 116, 15475-15484. (2019) [PMID: 31235585]
Christopher D. Lima, PhD
Chair, Structural Biology Program, SKI
- The Lima laboratory studies mechanisms underlying RNA processing as well as post-translational protein modification by ubiquitin-like proteins.
- PhD, Northwestern University
- Member, National Academy of Sciences (2020)
- Fellow of the American Academy of Arts and Sciences (2017)
- Investigator, Howard Hughes Medical Institute (2013)
- Louise and Allston Boyer Young Investigator in Basic Research, Memorial Sloan Kettering Cancer Center (2006)
- Scholar, Rita Allen Foundation (2003-2006)
- Mayor's Award for Excellence in Science and Technology, NYC Department of Cultural Affairs and New York Academy of Sciences (2003)
- Young Investigator Award, Arnold and Mabel Beckman Foundation (1999-2002)
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Christopher D. Lima discloses the following relationships and financial interests:
Ownership / Equity Interests
Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.